May 2, 2025
Coherus to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will…
Pharmaceuticals, Biotechnology and Life Sciences
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will…
FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) — Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer…
NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration…
OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technologyTAIPEI, Taiwan, May 01, 2025 (GLOBE NEWSWIRE) — OBI…
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal…
Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today…
Cincinnati, OH, April 30, 2025 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff…
SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) — Scorpius Holdings, Inc (OTC: SCPX) (“Scorpius” or “the Company”), an integrated contract…
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing…
FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage…